Acceptability and Feasibility of a Disease-specific Patient Portal in Adolescents With Sickle Cell Disease.
Kidwell, KM; Peugh, J; Westcott, E; Nwankwo, C; Britto, MT; Quinn, CT; Crosby, LE.
Journal of Pediatric Hematology/Oncology.
2019;
41:561-567.
Hydroxyurea for children with sickle cell anemia: Prescribe it early and often.
Ware, RE; McGann, PT; Quinn, CT.
Pediatric Blood and Cancer.
2019;
66.
Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.
McGann, PT; Niss, O; Dong, M; Marahatta, A; Howard, TA; Mizuno, T; Lane, A; Kalfa, TA; Malik, P; Quinn, CT; et al.
American Journal of Hematology.
2019;
94:871-879.
Hemoglobin Southampton complicated by cerebral ischemia, moyamoya, and hydroxyurea-induced methemoglobinemia.
Boucher, AA; Gurunathan, A; Taylor, JM; Ricci, KW; Vadivelu, S; Quinn, CT.
American Journal of Hematology.
2019;
94:949-954.
The Case for Pharmacogenetics-Guided Prescribing of Codeine in Children.
Gammal, RS; Caudle, KE; Quinn, CT; Wang, WC; Gaedigk, A; Prows, CA; Haidar, CE; Taylor, AK; Klein, TE; Sangkuhl, K; et al.
Clinical Pharmacology and Therapeutics.
2019;
105:1300-1302.
Abnormal submaximal cardiopulmonary exercise parameters predict impaired peak exercise performance in sickle cell anemia patients.
Powell, AW; Alsaied, T; Niss, O; Fleck, RJ; Malik, P; Quinn, CT; Mays, WA; Taylor, MD; Chin, C.
Pediatric Blood and Cancer.
2019;
66.
A Preliminary Investigation of the Psychometric Properties of PROMIS (R) Scales in Emerging Adults With Sickle Cell Disease.
Hildenbrand, AK; Quinn, CT; Mara, CA; Peugh, JL; McTate, EA; Britto, MT; Crosby, LE.
Health Psychology.
2019;
38:386-390.
Point-of-care screening for sickle cell disease in low-resource settings: A multi-center evaluation of HemoTypeSC, a novel rapid test.
Steele, C; Sinski, A; Asibey, J; Hardy-Dessources, M; Elana, G; Brennan, C; Odame, I; Hoppe, C; Geisberg, M; Serrao, E; et al.
American Journal of Hematology.
2019;
94:39-45.
Silent cerebral infarction: supply and demand.
Quinn, CT.
Blood.
2018;
132:1632-1634.
Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.
Gruppo, RA; Malan, D; Kapocsi, J; Nemes, L; Hay, CR M; Boggio, L; Chowdary, P; Tagariello, G; von Drygalski, A; Hua, F; et al.
Journal of Thrombosis and Haemostasis.
2018;
16:1984-1993.